Literature DB >> 30954942

A Pilot Study on Hepatobiliary Scintigraphy to Monitor Regional Liver Function in 90Y Radioembolization.

Sandra van der Velden1,2, Manon N G J A Braat3, Tim A Labeur4,5, Mike V Scholten3, Otto M van Delden4, Roelof J Bennink4, Hugo W A M de Jong3, Marnix G E H Lam3.   

Abstract

Radioembolization is increasingly used as a bridge to resection (i.e., radiation lobectomy). It combines ipsilateral tumor control with the induction of contralateral hypertrophy to facilitate lobar resection. The aim of this pilot study was to investigate the complementary value of hepatobiliary scintigraphy (HBS) before and after radioembolization in the assessment of the future remnant liver.
Methods: Consecutive patients with liver tumors who underwent HBS before and after 90Y radioembolization were included. Regional (treated/nontreated) and whole liver function and volume were determined on HBS and CT. Changes in regional liver function and volume were correlated with the functional liver absorbed doses, determined on 90Y PET/CT. In addition, the correlation between liver volume and function change was evaluated.
Results: Thirteen patients (10 hepatocellular carcinoma, 3 metastatic colorectal carcinoma) were included. Liver function of the treated part declined after radioembolization (HBS-pre, 4.0%/min/m2; HBS-post, 1.9%/min/m2; P = 0.001), whereas the function of the nontreated part increased (HBS-pre, 1.4%/min/m2; HBS-post, 2.8%/min/m2; P = 0.009). Likewise, treated volume decreased (pretreatment, 1,118.7 cm3; posttreatment, 870.7 cm3; P = 0.003), whereas the nontreated volume increased (pretreatment, 412.7 cm3; posttreatment, 577.6 cm3; P = 0.005). Bland-Altman analysis revealed a large bias (29%) between volume decrease and function decrease in the treated part and wide limits of agreement (-7.7%-65.6%). The bias between volume and function change was smaller (±6.0%) in the nontreated part of the liver, but limits of agreement were still wide (-117.9%-106.7%).
Conclusion: Radioembolization induces regional changes in liver function that are accurately detected by HBS. Limits of agreement between function and volume changes were wide, showing large individual differences. This finding indicates that HBS may have a complementary role in the management of patients for radiation lobectomy.
© 2019 by the Society of Nuclear Medicine and Molecular Imaging.

Entities:  

Keywords:  90Y; 99mTc-mebrofenin; hepatobiliary scintigraphy; radiation lobectomy; radioembolization

Year:  2019        PMID: 30954942      PMCID: PMC6785787          DOI: 10.2967/jnumed.118.224394

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  18 in total

1.  Dosimetric techniques in 90Y-microsphere therapy of liver cancer: The MIRD equations for dose calculations.

Authors:  Seza A Gulec; Geraldine Mesoloras; Michael Stabin
Journal:  J Nucl Med       Date:  2006-07       Impact factor: 10.057

2.  EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds.

Authors:  Francesco Giammarile; Lisa Bodei; Carlo Chiesa; Glenn Flux; Flavio Forrer; Françoise Kraeber-Bodere; Boudewijn Brans; Bieke Lambert; Mark Konijnenberg; Françoise Borson-Chazot; Jan Tennvall; Markus Luster
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-07       Impact factor: 9.236

3.  Outcomes of Surgical Resection after Radioembolization for Hepatocellular Carcinoma.

Authors:  Ahmed Gabr; Nadine Abouchaleh; Rehan Ali; Talia Baker; Juan Caicedo; Nitin Katariya; Michael Abecassis; Ahsun Riaz; Robert J Lewandowski; Riad Salem
Journal:  J Vasc Interv Radiol       Date:  2018-09-27       Impact factor: 3.464

4.  Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade.

Authors:  Philip J Johnson; Sarah Berhane; Chiaki Kagebayashi; Shinji Satomura; Mabel Teng; Helen L Reeves; James O'Beirne; Richard Fox; Anna Skowronska; Daniel Palmer; Winnie Yeo; Frankie Mo; Paul Lai; Mercedes Iñarrairaegui; Stephen L Chan; Bruno Sangro; Rebecca Miksad; Toshifumi Tada; Takashi Kumada; Hidenori Toyoda
Journal:  J Clin Oncol       Date:  2014-12-15       Impact factor: 44.544

5.  (99m)Tc-mebrofenin hepatobiliary scintigraphy with SPECT for the assessment of hepatic function and liver functional volume before partial hepatectomy.

Authors:  Wilmar de Graaf; Krijn P van Lienden; Thomas M van Gulik; Roelof J Bennink
Journal:  J Nucl Med       Date:  2010-01-15       Impact factor: 10.057

6.  Assessment of future remnant liver function using hepatobiliary scintigraphy in patients undergoing major liver resection.

Authors:  Wilmar de Graaf; Krijn P van Lienden; Sander Dinant; Joris J T H Roelofs; Olivier R C Busch; Dirk J Gouma; Roelof J Bennink; Thomas M van Gulik
Journal:  J Gastrointest Surg       Date:  2010-02       Impact factor: 3.452

7.  Radiation lobectomy: time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection.

Authors:  Michael Vouche; Robert J Lewandowski; Rohi Atassi; Khairuddin Memon; Vanessa L Gates; Robert K Ryu; Ron C Gaba; Mary F Mulcahy; Talia Baker; Kent Sato; Ryan Hickey; Daniel Ganger; Ahsun Riaz; Jonathan Fryer; Juan Carlos Caicedo; Michael Abecassis; Laura Kulik; Riad Salem
Journal:  J Hepatol       Date:  2013-06-25       Impact factor: 25.083

8.  Monitoring of Total and Regional Liver Function after SIRT.

Authors:  Roelof J Bennink; Kasia P Cieslak; Otto M van Delden; Krijn P van Lienden; Heinz-Josef Klümpen; Peter L Jansen; Thomas M van Gulik
Journal:  Front Oncol       Date:  2014-06-16       Impact factor: 6.244

9.  Dosimetric parameters predicting contralateral liver hypertrophy after unilobar radioembolization of hepatocellular carcinoma.

Authors:  Xavier Palard; Julien Edeline; Yan Rolland; Samuel Le Sourd; Marc Pracht; Sophie Laffont; Laurence Lenoir; Karim Boudjema; Thomas Ugen; Vanessa Brun; Habiba Mesbah; Laure-Anne Haumont; Pascal Loyer; Etienne Garin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-11-25       Impact factor: 9.236

10.  Hepatobiliary scintigraphy may improve radioembolization treatment planning in HCC patients.

Authors:  Manon N G J A Braat; Hugo W de Jong; Beatrijs A Seinstra; Mike V Scholten; Maurice A A J van den Bosch; Marnix G E H Lam
Journal:  EJNMMI Res       Date:  2017-01-05       Impact factor: 3.138

View more
  4 in total

1.  Regional liver function analysis with gadoxetic acid-enhanced MRI and virtual hepatectomy: prediction of postoperative short-term outcomes for HCC.

Authors:  Mengqi Huang; Shunli Shen; Huasong Cai; Zhenpeng Peng; Wan Hang Keith Chiu; Zi-Ping Li; Baogang Peng; Shi-Ting Feng
Journal:  Eur Radiol       Date:  2021-01-15       Impact factor: 5.315

2.  Clinical, dosimetric, and reporting considerations for Y-90 glass microspheres in hepatocellular carcinoma: updated 2022 recommendations from an international multidisciplinary working group.

Authors:  Riad Salem; Siddharth A Padia; Marnix Lam; Carlo Chiesa; Paul Haste; Bruno Sangro; Beau Toskich; Kirk Fowers; Joseph M Herman; S Cheenu Kappadath; Thomas Leung; Daniel Y Sze; Edward Kim; Etienne Garin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-09-17       Impact factor: 10.057

Review 3.  Optimization of the future remnant liver: review of the current strategies in Europe.

Authors:  Riccardo Memeo; Maria Conticchio; Emmanuel Deshayes; Silvio Nadalin; Astrid Herrero; Boris Guiu; Fabrizio Panaro
Journal:  Hepatobiliary Surg Nutr       Date:  2021-06       Impact factor: 7.293

4.  Hepatobiliary Scintigraphy and Glass 90Y Radioembolization with Personalized Dosimetry: Dynamic Changes in Treated and Nontreated Liver.

Authors:  Carole Allimant; Emmanuel Deshayes; Marilyne Kafrouni; Lore Santoro; Delphine de Verbizier; Marjolaine Fourcade; Christophe Cassinotto; Margaux Hermida; Chloé Guillot; Denis Mariano-Goulart; Boris Guiu
Journal:  Diagnostics (Basel)       Date:  2021-05-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.